Daewoong Pharmaceutical has supplied the AI-based bed monitoring system 'thynC' to Samsung Medical Center's smart hospital and has begun pilot operations. This future-oriented smart hospital model integrates the ring-type continuous blood pressure monitor 'Carton' to monitor key vital signs, including electrocardiograms and blood pressure, 24 hours a day.
On July 20, Daewoong Pharmaceutical announced that it has partnered with Searus and Skylabs to provide the AI-based bed monitoring system 'thynC' with added blood pressure monitoring capabilities for Samsung Medical Center's smart hospital pilot.
This implementation is part of Samsung Medical Center's initiative to establish a 'smart hospital.' The center is currently operating two patient rooms within its main building as a digital transformation testbed, aiming to gradually enhance the patient experience through advanced ward monitoring.
'thynC' is responsible for monitoring key vital signs such as electrocardiograms, blood pressure, and oxygen saturation. The newly introduced system combines the existing smart bed monitoring system with the ring-type continuous blood pressure monitor 'Carton' to create an integrated digital healthcare platform.
When patients wear a compact wearable device, vital signs such as electrocardiograms, oxygen saturation, and blood pressure are collected in real time. The collected data is linked to a central monitor, allowing medical staff to continuously check patient conditions around the clock.
The AI analyzes the collected vital signs and promptly alerts medical personnel to warning signs of serious arrhythmias that may occur before cardiac arrest or death. It is also expected to reduce the burden of repeated vital sign measurements during nighttime, improving the sleep environment for patients and enhancing nursing staff efficiency.
Earlier this year, Daewoong Pharmaceutical signed a contract to introduce 'thynC' in the cardiology ward of Samsung Medical Center. By the third quarter of 2026, the installation of the monitoring system focusing on electrocardiogram and oxygen saturation measurements will be completed in 39 beds. The company has previously announced plans to expand the supply of 'thynC' to over 100,000 beds and aims to achieve annual sales of 300 billion won in the digital healthcare sector.
A Daewoong Pharmaceutical official stated, "We will continue to develop a smart hospital model that provides precise clinical judgment for medical staff and a safe hospitalization environment for patients."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.